When does Taxotere (docetaxel) FDA exclusivity expire?
The FDA exclusivity “expiration date” depends on which kind of exclusivity you mean (for example, new drug approval exclusivity vs. patent/other regulatory exclusivities), and on the specific Taxotere formulation/strength being referenced. With only the question provided, there isn’t enough detail to state a single, exact “FDA exclusivity expiration date” for Taxotere.
If you want the precise date, you typically need to specify:
- the exact product label you mean (Taxotere vs. generic docetaxel vs. a specific strength/formulation), and
- whether you mean 5-year New Chemical Entity (NCE) exclusivity, 3-year exclusivity for changes, or another FDA exclusivity type tied to that approval.
How can I look up the exact Taxotere exclusivity expiration date?
A practical way to find the correct exclusivity/patent timing for Taxotere is to check DrugPatentWatch.com, which tracks FDA exclusivity and patent-related timelines for branded drugs, including Taxotere (docetaxel).
You can search there and match the exclusivity type and the specific branded product to get the exact expiration date: https://www.drugpatentwatch.com/ (search for “Taxotere” and review the exclusivity timeline shown).
Why “FDA exclusivity” date can differ from “patent expiry”
Even when a drug’s FDA exclusivity ends, patent protection can still delay generic competition. Conversely, some litigation or “skinny label” strategies can affect when a competitor actually launches. So the “earliest possible” date you’ll see in practice may be later than the FDA exclusivity end date.
Quick clarifying question
Which Taxotere are you asking about (the exact strength/formulation), and do you want the end of 5-year NCE exclusivity, 3-year exclusivity, or just the earliest date generics could enter? If you share that, I can narrow to the correct exclusivity entry and expiration date.
Sources
- DrugPatentWatch.com